Honeysoy – You present a good argument; it is elegantly put. I...

Honeysoy – You present a good argument; it is elegantly put. I agree that what someone will pay for a share is about perception; but it is, at this point, we part the way. You go on to presume there is only one type of investor and only one way of assessing value. (reading the score board as you put it).
It is a good time to consider this because the Company has advised the market, it is embarking on a planned “step change” in its development aimed at delivering improved profitability, as it meets the new demands of increased scale in its operations. A progress report on this should appear sometime soon.

Two groups operate in the share market – for simplicity, let us call them TRADERS and INVESTORS. Each looks for different things. I smile – I note from your various posts you review and perceive as a Trader : yet you have an underlying streak of “the investor” in your hopes and aspirations.For the moment you and Muya perceive as Traders whereas I and others perceive as Investors.

It is an acknowledged fact on the ASX that share price does not always reflect a shares value. It is common wisdom, expressed every day in the financial press - if you want to find bargains and “Hidden Gems” then look amongst the “Small and Micro Caps”.UCM is just such a share.

I am an Investor – I like to base my judgements not on perception - but on solid principles and research. Let me tell you what I see in UCM as an Investor:
I seek two things – reasonable safety and capital growth. Protection of a large Moat is a bonus.
UCM total revenue has grown at a Compound Annual Growth Rate of 24% for the last 9 years. UCM had a 1 Yr Earnings per Share Growth of 36.1% last year.
Over the last 9 Years, the Company has sold $30m worth of its flagship product the USCOM 1A in a single model, made in Australia. This year it is expanding its 1A range with two specialist models that will be manufactured in China to fulfill a specialist China demand. Supported by over 400 peer reviewed publications confirming the benefits of USCOM 1A. The 1A is now the world recognized standard of care in Management of adult and children’s sepsis and for the management of maternal health. Its forward market is huge.

This solid steady background growth is overlooked by the “Score Board watcher”. The company is now intermittently profitable and cash flow positive with NO DEBT. It has established an international organization with its head Office in Singapore - having balanced its available expenditure against its growth aspirations over the years to ensure its steady compound growth. It has survived the greatest financial crisis of our times and the greatest medical pandemic of our times. It has chosen to do this while minimizing its capital demands on its loyal shareholders.It is currently bringing 6 new products to market.

Uscom has proven, honest and qualified leadership, a small 4 member experienced Board, and an impressive 7 member Medical & Technology Advisory Board.
Uscom owns more than 30 patents and IP grants worldwide, with multiple FDA and NMPA applications in progress and due for approvals.
Uscom earned $5.5m total revenue last year, has $5.5m in cash, and has a current Market Capitalization of only $19.3M.

There are virtually no sellers at the current price - the Board and management have all bought shares heavily over the last 12 months – Does ALL this not tell you something – that has never found its way to the Score Board???

Good fortune to all